GERALDEI PAUL: Open Payments
NPI 1609485945 · FALL RIVER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$854 in 44 payments from 10 companies in 2025. Trend: 2023 $1,676 · 2024 $1,469 · 2025 $854
Food & beverage: $854
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $236 |
| Otsuka America Pharmaceutical, Inc. | 9 | $201 |
| ABBVIE INC. | 9 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Sage Therapeutics, LLC | 1 | $33 |
| Neurocrine BioSciences, Inc. | 2 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Corium, LLC | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: ARISTADA, REXULTI, VRAYLAR, CAPLYTA, Qelbree, ZURZUVAE, INGREZZA, Jornay PM.
Industry payments across MA — which companies pay providers there.
